AMBI · Insider Trading
Ambipar Emergency Response
Every open-market purchase and sale reported by AMBI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2014-11-12 | Annette North | Senior VP and General Counsel | D | −169,502 deriv. | — |
| 2014-11-12 | Mark G Foletta | Director | D | −22,000 deriv. | — |
| 2014-11-12 | Athena Countouriotis | Chief Medical Officer | D | −241,008 deriv. | — |
| 2014-11-12 | Alan Fuhrman | Chief Financial Officer | D | −6,309 | −$94.64K |
| 2014-11-12 | Jeffrey S. Hatfield | Director | D | −14,000 deriv. | — |
| 2014-11-12 | Faheem Hasnain | Director | D | −180,181 deriv. | — |
| 2014-11-12 | Michael A Martino | Chief Executive Officer | D | −843,553 deriv. | — |
| 2014-09-04 | Steve Elms | Director | X | +2,362 | +$15.73K |
| 2014-07-16 | Faheem Hasnain | Director | A | +20,000 deriv. | — |
| 2014-01-27 | Mark G Foletta | Director | A | +14,000 deriv. | — |
| 2014-01-10 | Annette North | Senior VP & General Counsel | A | +40,000 deriv. | — |
| 2014-01-10 | Michael A Martino | President and CEO | A | +91,700 deriv. | — |
| 2014-01-10 | Athena Countouriotis | Chief Medical Officer | A | +45,000 deriv. | — |
| 2014-01-10 | Alan Fuhrman | Chief Financial Officer | A | +45,000 deriv. | — |
| 2013-10-16 | James B. Tananbaum | 10%+ Owner | Buy | +238,707 | +$1.65M |
| 2013-07-18 | Athena Countouriotis | Chief Medical Officer | A | +76,481 deriv. | — |
| 2013-07-18 | Alan Fuhrman | Chief Financial Officer | A | −68,369 deriv. | — |
| 2013-07-18 | Michael A Martino | President and CEO | A | +46,083 deriv. | — |
| 2013-05-24 | David P Bonita | Director | Buy | +33,800 | +$233.51K |
| 2013-05-24 | ORBIMED ADVISORS LLC | 10%+ Owner | Buy | +101,400 | +$700.52K |
| 2013-05-23 | Steve Elms | Director | X | +103,712 | +$2.49K |
| 2013-05-22 | David P Bonita | Director | MIXED | +1,456,660 | +$5.42M |
| 2013-05-22 | OrbiMed Capital GP III LLC | 10%+ Owner | MIXED | +4,369,980 | +$16.27M |
| 2013-05-21 | David Ross Parkinson | Director | A | −7,085 deriv. | — |
| 2013-05-21 | Faheem Hasnain | Director | A | −7,085 deriv. | — |
| 2013-05-21 | Allan P Marchington | Director | MIXED | +1,326,821 | +$3.45M |
| 2013-05-21 | Isai Peimer | Director | A | −7,085 deriv. | — |
| 2013-05-21 | Standish Fleming | Director | MIXED | +966,011 | +$2.11M |
| 2013-05-21 | Joseph Regan | Director | A | −7,085 deriv. | — |
| 2013-05-21 | Steve Elms | Director | MIXED | +1,546,225 | +$3.39M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AMBI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.